Neurological Disorder Diagnostics Market was valued at US$ 10,774.6 Mn in 2017, and is expected to witness a CAGR of 7.3% over the forecast period (2018 – 2026) By Siemens Healthineers, Koninklijke Philips N.V., General Electric Company, Esaote SpA

Neurological disorder diagnostic tools are those used in diagnosis of various neurological disorders. Neurological disorders can be diagnosed with the use of imaging and in vitro diagnostics techniques. Imaging techniques such as Computed Tomography (CT) and Magnetic Resonance Imaging (MRI) are used to create detailed images of organs, bones, soft tissue, blood vessels and different parts of body, while vitro diagnostic techniques consists of techniques such as biopsy, biomarker, blood test, urine test, and genetic testing.

Download PDF Brochure of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-pdf/1867

Market Dynamics

Product launches and approvals of novel neurological diagnostic products is expected to be a major driver for growth of the global neurological disorder diagnostics. For instance, in 2016, Koninklijke Philips N.V. launched its latest Philips IQon Spectral CT in Canada. The latest Philips IQon Spectral CT is the world’s first and only spectral detector CT, designed specifically for spectral imaging. With a new dual-layer spectral detector, the IQon Spectral CT has added spectral resolution to conventional CT scanning. Increasing research and development activities for development of novel diagnosis techniques for neurological disorder is also expected to fuel the market growth.

Frequent launches and approvals of novel neurological disorder diagnostics products is expected to drive growth of the market

In the recent past, key players in the market had received approvals and had launched a number of novel technological advanced neurological disorder diagnosis devices in the market, and this is expected to aid in neurological disorder diagnostics market growth. For instance, in April 2018, Canon Medical Systems Corporation launched 1.5T MRI System, Vantage Orian. In April 2018, Siemens Healthineers received U.S. FDA approval for its new SOMATOM go.All and SOMATOM go.Top computed tomography (CT) systems. SOMATOM go.All has 64-slice and provides 0.33-second rotation time, stellar detector technology, and a robust 75 kW generator. SOMATOM go.Top has 128-slice and provides fast scanning. Furthermore, in 2017, Neusoft Medical Systems received U.S. FDA approval for NeuViz Prime CT Scanner.

Increasing strategic collaborations for development of new diagnostic tools is expected to propel the market growth

Strategic collaboration among key players in the market is also expected to be another factor fueling growth of the global neurological disorder diagnosis market growth. For instance, in March 2018, Canon Medical Systems, Kumamoto University, and University of Bordeaux entered into collaborative research for development of deep learning technology in magnetic resonance imaging. In 2017, York Instruments Ltd. signed an agreement for three Magnetoencephalography Systems with three leading universities. The University of York, the University of Glasgow in the U.K., and Germany’s University of Konstanz partnered with York Instruments to develop this technology.

Competitive Analysis

Key players operating in the neurological disorder diagnostics market include Healthineers, Koninklijke Philips N.V., General Electric Company, Esaote SpA, NeuroLogica Corporation, Masimo Corporation, York Instruments Ltd., Neusoft Medical Systems, and Canon Medical Systems Corporation

Request For Customization Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-customization/1867

Detailed Segmentation:

Global Neurological disorder diagnostics, By Technology :
Imaging
Computed Tomography (CT)
Magnetic Resonance Imaging (MRI)
Nuclear Medicine Imaging
Positron Emission Tomography (PET)
Single-Photon Emission Computed Tomography (SPECT)
Near Infrared Spectroscopic Imaging (NIRS)
Electroencephalography (EEG)
Magnetoencephalography (MEG)
In Vitro Diagnostics
Biomarker
Biopsy
Others

Global Neurological disorder diagnostics, By Disease Indication:
Genetic Neurological Disorders
Alzheimer’s Disease (AD)
Parkinson’s Disease (PD)
Amyotrophic Lateral Sclerosis (ALS)
Huntington's Disease (HD)
Others

Immunological Neurological Disorders
Multiple Sclerosis
Others
Paraneoplastic Syndrome
Paraproteinemic neuropathies
Others

Global Neurological disorder diagnostics, By End User:
Hospitals & Clinics
Diagnostic Centers
Ambulatory Care Centers

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave, 
#3200 
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.